article thumbnail

What are Debt Warrants and How Do They Work for Startups?

Lighter Capital

Debt warrant example: Roku Here’s a real-life example of how debt warrants work. When Roku had its IPO in 2017, a venture lender had a warrant for 400,000 shares of Roku’s preferred stock with a strike price of $9.17340. No, not all startup loans require debt warrants in the agreement terms.

article thumbnail

Have Your Cake, and Closing Too: Invoking Prevention Doctrine, Delaware Chancery Court Grants Seller’s Request for Specific Performance in COVID-Related M&A Dispute

Cooley M&A

In reaching this order, the court applied the prevention doctrine, finding that the unavailability of buyer’s debt financing did not permit buyer to circumvent its obligation to close because buyer materially contributed to the debt financing being unavailable.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Corporate Tax Burden: Facts and Fiction

Musings on Markets

I will begin by laying out the pathways through which corporate taxes affect company value, and then looking at how the 2017 tax reform act, which lowered the federal tax rate from 35% to 21%, has affected corporate behavior. In a more telling statistic, the dollar value of taxes paid increased between 2017 and 2019 by 1.4%

article thumbnail

Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)

Benzinga

Originally approved in 2017 for CRS with nasal polyps with a commercial focus on ear, nose, and throat (ENT) and allergy specialists, the XHANCE label was broadened in 2024 to include an additional indication for CRS without nasal polyps. The Boards of both Paratek and Optinose have unanimously approved the transaction.